Dr. Daniel Liedtke to be appointed CEO of Hirslanden

Mediclinic International plc, the international private healthcare services group, today announces that its Swiss operating division, Hirslanden, has appointed Dr Daniel Liedtke as successor to Chief Executive Officer, Dr Ole Wiesinger. After more than ten years successfully leading Hirslanden and establishing the business as the leading private hospital group in Switzerland, Dr Ole Wiesinger will be retiring from his role on 1 January 2019, following a hand over period.

Dr Liedtke, 48, joined Hirslanden in 2001 and has subsequently held several senior roles within the business. He was Deputy Director at Hirslanden Klinik St. Anna in Luzern, before becoming Hospital Director of Klinik Hirslanden in Zurich between 2008 to 2015. In 2015, he was appointed to the Hirslanden Executive Committee as Chief Operating Officer, playing an instrumental role in the successful leadership of the business including the implementation of the ongoing Hirslanden 2020 strategic programme. Dr Liedtke is an expert on the Swiss healthcare system and has a proven track record in the development of new business models in the clinical environment. The appointment follows a comprehensive assessment process led by Mediclinic International Executives and Board members, who were unanimous in their decision to appoint Dr Liedtke, and demonstrates the strength of senior management across the Group.

Under Dr Wiesinger’s leadership, Hirslanden expanded its footprint from 13 hospitals in 2007 to the current portfolio of 18 hospitals through a series of successful acquisitions, the latest being Klinik Linde in Biel and Clinique des Grangettes in Geneva. Hirslanden now operates four outpatient clinics and has expanded in the fields of radiology and radiotherapy to broaden the overall service offering to patients in Switzerland. During Ole Wiesinger's ten-year term in office, turnover increased from CHF 1091 million to CHF 1735 million, and the number of employees rose from 5224 to 9635 during the same period. Significant investment has been made to enhance the quality of patient care which, together with the support from doctors, clinical staff and other employees, has enabled Hirslanden to retain its leading position in the Swiss private healthcare market. Dr Wiesinger will continue to provide support to the business until the end of March 2019.

Commenting today, Dr Ronnie van der Merwe, Chief Executive Officer of Mediclinic International said:

"On behalf of Mediclinic International and Hirslanden, I would like to express my sincere thanks to Ole for the many years he has dedicated to Hirslanden and for his outstanding leadership of the business. We wish him every success in his future as he explores new opportunities. I am very pleased to welcome Dr Daniel Liedtke as the new CEO of Hirslanden. He has demonstrated an impressive track record and in-depth knowledge of our Swiss business and the local healthcare market. His detailed involvement in the current Hirslanden 2020 strategic programme and understanding of our core business makes him the ideal person to continue the implementation of the programme and lead the business. We welcome his enthusiastic and energetic approach on the Mediclinic International Executive Committee as we work together to deliver long term success across the Group."

Dr Ole Wiesinger, CEO of Hirslanden, commented:

"I look back on the successful career I have had at Hirslanden and I would like to take this opportunity to thank the many talented people who I have worked alongside, during my time at Hirslanden, especially our almost 10,000 employees and 2,000 doctors. I feel that now is the right time to begin a new chapter. It has always been important to me to give back some of the success and experiences from my career and I hope to do this in the future through seeking professional opportunities such as board of director mandates, teaching posts and continuing engagement in a number of charitable endeavors. I wish my successor, Dr Daniel Liedtke, the same warm welcome inside and outside the company that I experienced and know from working closely with him for the past ten years that he is capable of achieving great success as CEO of Hirslanden.“

Dr Daniel Liedtke, COO of Hirslanden, commented:

"I am delighted to be taking on the role of Chief Executive Officer at Hirslanden, having spent 17 years working with the excellent team of doctors, clinical staff and employees, as Chief Operating Officer and in other roles. The team delivers best-in-class performance for patients every day, making Hirslanden not only the leading private healthcare group in Switzerland but recognised internationally for the quality of its clinical care. In the role, I will, as Ole has done successfully, seek to build on this position of strength as we navigate through the current regulatory environment and ensure the successful deployment of the Hirslanden 2020 strategic programme.“
 

About Mediclinic International plc
Mediclinic is an international private healthcare services group with operating divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed and UK-based private healthcare group. 

Mediclinic comprises 76 hospitals and 29 clinics. Hirslanden operates 18 private hospitals and 4 clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operates 48 hospitals and 3 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100 inpatient beds in total; and Mediclinic Middle East operates 7 hospitals and 22 clinics with more than 800 inpatient beds in the United Arab Emirates.

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia.

 

For further information, please contact:  

Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations 
ir@mediclinic.com
+44 (0)20 3786 8181 

Media queries 
Hirslanden
Frank Nehlig, Head of Corporate Communications 
medien@hirslanden.ch 
+41 44 388 75 85 

FTI Consulting  
Brett Pollard/Debbie Scott – UK 
+44 (0)20 3727 1000  
Sherryn Schooling – South Africa  
+27 (0)21 487 9000  

James Arnold

Head of Investor Relations
Mediclinic International plc
6th Floor
65 Gresham Street
London EC2V 7NQ
United Kingdom

Frank Nehlig

Head of Corporate Communications
Corporate Office
Boulevard Lilienthal 2
CH-8152 Glattpark